ccl13  (R&D Systems)

Journal: Scientific Reports

Article Title: Immuno-transcriptomic analysis based on machine learning identifies immunity signature genes of chronic rhinosinusitis with nasal polyps

doi: 10.1038/s41598-025-02508-8

Figure Lengend Snippet: Gene expression levels of candidate genes. Gene expression levels of CXCR1 ( A ), CCL13 ( B ), PPBP ( C ), CCR3 ( D ) and MMP9 ( E ) in CRSwNP and control samples. Gene expression levels of CXCR1 ( F ), CCL13 ( G ), PPBP ( H ), CCR3 ( I ) and MMP9 ( J ) in different inflammatory endotypes of CRSwNP. (* P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant).

Article Snippet: The primary antibodies were as follows: CXCR1 (1:500; Servicebio, GB11625-100), CCL13(1:1000; Proteintech, Ag24131),PPBP(1:50; Proteintech, 13313-1-AP),CCR3(1:200; Proteintech, 22351-1-AP), MMP-9(1:500; Proteintech, 10375-2-AP), GAPDH(1:3000; Servicebio, GB15004-100).

Techniques: Gene Expression, Control

Journal: Scientific Reports

Article Title: Immuno-transcriptomic analysis based on machine learning identifies immunity signature genes of chronic rhinosinusitis with nasal polyps

doi: 10.1038/s41598-025-02508-8

Figure Lengend Snippet: Candidate gene protein expression levels in normal mucosal tissues and chronic rhinosinusitis with nasal polyps (CRSwNP) tissues were analysed using IHC staining. Unpaired t-tests were used to determine the significant differences for candidate gene protein expression between the normal mucosal(n = 5) and CRSwNP (n = 5) groups. ( A ) CXCR1. ( B ) CCL13. ( C ) PPBP. ( D ) CCR3. ( E ) MMP9. (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

Article Snippet: The primary antibodies were as follows: CXCR1 (1:500; Servicebio, GB11625-100), CCL13(1:1000; Proteintech, Ag24131),PPBP(1:50; Proteintech, 13313-1-AP),CCR3(1:200; Proteintech, 22351-1-AP), MMP-9(1:500; Proteintech, 10375-2-AP), GAPDH(1:3000; Servicebio, GB15004-100).

Techniques: Expressing, Immunohistochemistry

Journal: Neoplasia (New York, N.Y.)

Article Title: High p16 INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis

doi: 10.1016/j.neo.2024.101116

Figure Lengend Snippet: In vitro Senescent GBM Model via p16 INK4A Overexpression Exhibit Senescence Phenotype. A The protein (upper panel) and mRNA expression levels (lower panel) of p16 INK4A ( CDKN2A ) in SNU201 after transduction with either an empty vector (Empty) or a p16 INK4A -overexpression vector (p16 INK4A ) is shown. kDa: kilodalton. NC: non-transduced SNU201. B The morphology of SNU201 cells post-transduction is depicted in the left panel, with SA-β-Gal staining results in the middle panel and quantification data on the right. C-D Real-time PCR data for representative SASPs and chemokines in SNU201 cells transduced with either vector. E-F IHC analysis for CCL2 and CCL13 in GBM tissues, with quantification data in the lower right panel. Statistical differences in ( A-D ) were analyzed using Student's t-test while those in ( E-F ) were analyzed using the Chi-square test.

Article Snippet: IHC was conducted using the following primary antibodies: p16 INK4A prediluted solution (805–4713; Roche, Tucson, AZ); αSMA, 1:200 (ab5694, Abcam, Cambridge, UK); CD68, 1:2500 (NBP2-48923, Novus Biologicals, Centennial, CO); GFAP, pre-diluted solution (IR524, Dako, Denmark); CD45, 1:1000 (ab8216, Abcam); CD11b, 1:4000 (ab133357, Abcam); CD3, 1:150 (ab135372, Abcam); Cleaved caspase-3, 1:400 (9661S, Cell Signaling Technology, Danvers, MA); CCL2, 1:100 (MAB2791, R&D Systems, Minneapolis, MN); CCL13 1:50 (sc-271124, Santa Cruz Biotechnology, Dallas, TX).

Techniques: In Vitro, Over Expression, Expressing, Transduction, Plasmid Preparation, Staining, Real-time Polymerase Chain Reaction

Journal: Neoplasia (New York, N.Y.)

Article Title: High p16 INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis

doi: 10.1016/j.neo.2024.101116

Figure Lengend Snippet: The SASPs from Senescent GBM Cells Recruit Immune Cells in vitro . A The left panel shows a migration assay schematic, with quantification of migrated cells in the right panel (Empty: CM from empty vector-transduced SNU201; p16 INK4A : CM from p16 INK4A -overexpressed SNU201). B The left panel depicts a migration assay with si CCL2 or si CCL13 treatment in p16 INK4A -overexpressing SNU201, while the right panel shows CDKN2A (p16 INK4A ) mRNA expression levels. I The mRNA expression levels of CCL2 and CCL13 are shown in the left and right panels, respectively. J The left panel shows the number of migrated THP-1 cells with siControl or si CCL2 in p16 INK4A -overexpressed SNU201, and the right panel shows migrated Jurkat cells with siControl or si CCL13 . Statistical differences in ( A and C-D ) were analyzed using Student's t-test. NC: non-treated control; Empty: empty vector-transduced cells; p16 INK4A : p16 INK4A -overexpression vector-transduced cells. All graphs present mean ± standard deviation.

Article Snippet: IHC was conducted using the following primary antibodies: p16 INK4A prediluted solution (805–4713; Roche, Tucson, AZ); αSMA, 1:200 (ab5694, Abcam, Cambridge, UK); CD68, 1:2500 (NBP2-48923, Novus Biologicals, Centennial, CO); GFAP, pre-diluted solution (IR524, Dako, Denmark); CD45, 1:1000 (ab8216, Abcam); CD11b, 1:4000 (ab133357, Abcam); CD3, 1:150 (ab135372, Abcam); Cleaved caspase-3, 1:400 (9661S, Cell Signaling Technology, Danvers, MA); CCL2, 1:100 (MAB2791, R&D Systems, Minneapolis, MN); CCL13 1:50 (sc-271124, Santa Cruz Biotechnology, Dallas, TX).

Techniques: In Vitro, Migration, Plasmid Preparation, Expressing, Control, Over Expression, Standard Deviation

Journal: Neoplasia (New York, N.Y.)

Article Title: High p16 INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis

doi: 10.1016/j.neo.2024.101116

Figure Lengend Snippet: The CCL13 expression is related to prognosis of GBM in TCGA dataset. A The survival graphs of GBM based on CCL13 expression (left panel) and CCL2 expression (right panel) are derived from the TCGA GBM-PanCancer dataset. B The schematic image illustrates how the presence of p16 INK4A -high GBM is linked to the tumor immune microenvironment and impacts patient prognosis.

Article Snippet: IHC was conducted using the following primary antibodies: p16 INK4A prediluted solution (805–4713; Roche, Tucson, AZ); αSMA, 1:200 (ab5694, Abcam, Cambridge, UK); CD68, 1:2500 (NBP2-48923, Novus Biologicals, Centennial, CO); GFAP, pre-diluted solution (IR524, Dako, Denmark); CD45, 1:1000 (ab8216, Abcam); CD11b, 1:4000 (ab133357, Abcam); CD3, 1:150 (ab135372, Abcam); Cleaved caspase-3, 1:400 (9661S, Cell Signaling Technology, Danvers, MA); CCL2, 1:100 (MAB2791, R&D Systems, Minneapolis, MN); CCL13 1:50 (sc-271124, Santa Cruz Biotechnology, Dallas, TX).

Techniques: Expressing, Derivative Assay

Journal: Osteoarthritis and cartilage

Article Title: Role of the C-C chemokine Receptor-2 in a Murine Model of Injury-induced Osteoarthritis

doi: 10.1016/j.joca.2016.11.004

Figure Lengend Snippet: Levels of (A) CCL12 and (B) other’s CCR2 ligands (CCL2, CCL8, CCL7, CCL13) were measured by immunohistochemistry (IHC) in articular cartilage sections obtained from medial knee joints of mice at the indicated time points after DMM or sham control surgery. Brown is immunopositive staining. DMM-operated knees at 4, 8 and 12 weeks post-surgery were immunostained with antibodies to CCR2 and protein levels where visualized in (C) medial tibial cartilage, (D) chondrocytes of the growth plate and (E) synovium. Images are representative of 6 different mice for each of the experimental points described. Scale bars are 100 µm.

Article Snippet: Rabbit polyclonal anti-CCL2 (orb13563), CCL8 (orb13565), CCL7 (orb13567), CCL13 (orb13285) and CCL12 (orb13284) antibodies were from Biorbyt; rabbit polyclonal anti-CCR2 was from Novusbio (NB100-701); anti-CollagenX (ab58632), anti-Osteocalcin (ab10911) and mouse monoclonal anti-MMP-13 (ab3208) antibodies were from Abcam; The CCR-2 antagonist RS-504393 was from Tocris Bioscience.

Techniques: Immunohistochemistry, Staining

Journal: Osteoarthritis and cartilage

Article Title: Role of the C-C chemokine Receptor-2 in a Murine Model of Injury-induced Osteoarthritis

doi: 10.1016/j.joca.2016.11.004

Figure Lengend Snippet: Protein levels of CCL12 were visualized by IHC in the bone tissues (A) 2 wks after DMM/sham, as well as (B) 4 and 8 wks post-surgery. Protein levels of (C) CCL2, CCL8, CCL7, CCL13, as well as (D) CCR2 were visualized in bone tissue by IHC at the indicated time points. (E) Protein levels and mRNA expression of Col10 were visualized by IHC and ISH, respectively, in medial femurs obtained from mice 1wk after DMM/sham surgery. Osteophytes were visualized by (F) μCT analyses and (G) OCN protein/mRNA levels (IHC and ISH) in medial femurs and tibiae obtained from mice 2wks after DMM/sham surgery. Images are representative of 6 different mice for each of the experimental points described. Scale bars are 100 µm.

Article Snippet: Rabbit polyclonal anti-CCL2 (orb13563), CCL8 (orb13565), CCL7 (orb13567), CCL13 (orb13285) and CCL12 (orb13284) antibodies were from Biorbyt; rabbit polyclonal anti-CCR2 was from Novusbio (NB100-701); anti-CollagenX (ab58632), anti-Osteocalcin (ab10911) and mouse monoclonal anti-MMP-13 (ab3208) antibodies were from Abcam; The CCR-2 antagonist RS-504393 was from Tocris Bioscience.

Techniques: Expressing